Northeast Gi Research Division — research payments reported

By program year

3 rows

Year	Kind	Amount	Payments
2021	Research	$49,826	240
2020	Research	$151,609	3
2019	Research	$47,306	3

Breakdown

Who paid Research payments · program years 2019–2021

E.R. Squibb & Sons, L.L.C. $167,191 5 payments
Novartis Pharmaceuticals Corporation $45,560 3 payments
Novo Nordisk AS $35,989 238 payments

Studies the money was for Research payments · program years 2019–2021

Phase IIB Study - F3 24 wk $100,568 1 payment
A Randomized Double Blind Multicenter Study to Assess the Safety Tolerability and Efficacy of A Combination Treatment of Tropifexor Ljn452 and Cenicriviroc CVC in Adult Patients With Nonalcoholic Steatohepatitis Nash and Liver Fibrosis $45,560 3 payments
Nn9931-4553 $35,989 238 payments
A Phase 2B Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Bms-986036 Peg-Fgf21 in Adults With Nonalcoholic Steatohepatitis Nash and Stage 3 Liver Fibrosis $30,141 1 payment
A Phase 2B Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Bms-986036 (Peg-Fgf21) in Adults With Nonalcoholic Steatohepatitis (Nash) and Compensated Liver Cirrhosis $18,850 1 payment
A Phase 2B Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Bms-986036 (Peg-Fgf21) in Adults With Nonalcoholic Steatohepatitis (Nash) and Stage 3 Liver Fibrosis $13,824 1 payment
A Phase 2B Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Bms-986036 Peg-Fgf21 in Adults With Nonalcoholic Steatohepatitis Nash and Compensated Liver Cirrhosis $3,808 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.